drugset / Trial / NCT07136428
Asciminib in HER2+ Breast Cancer Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.
Timeline
- Start
- 2026-07
- Primary completion
- 2030-11-01
- Completion
- 2032-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asciminib | Unknown | 40 mg | Oral |
| Subject | Asciminib | Unknown | 80 mg | Oral |
| Subject | Asciminib | Unknown | 200 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |